You are here

ADVANCED VISION THERAPIES, INC.

Company Information
Address
ADVANCED VISION THERAPIES, INC. 9700 GREAT SENECA HWY
ROCKVILLE, MD 21754 0330
United States



Information

UEI: N/A

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Novel Strategy for BIV Vector Site-Specific Integration

    Amount: $349,780.00

    DESCRIPTION (provided by applicant): Lentivirus-based gene transfer systems represent a promising gene delivery technology, as they integrate into the genome of the target cell and mediate sustained e ...

    SBIRPhase I2006Department of Health and Human Services National Institutes of Health
  2. A Novel BIV vector pseudotyped with thogoto virus gp75

    Amount: $149,800.00

    DESCRIPTION (provided by applicant): Lentivirus-based gene transfer systems represent a promising gene delivery technology, as they integrate into the genome of the target cell and mediate sustained e ...

    SBIRPhase I2006Department of Health and Human Services National Institutes of Health
  3. Novel Therapy for Wet Age-Related Macular Degeneration

    Amount: $2,160,130.00

    DESCRIPTION (provided by applicant): Wet age-related macular degeneration (AMD) is the leading cause of blindness in the developed world and represents a disease with a great unmet medical need. The b ...

    SBIRPhase II2005Department of Health and Human Services National Institutes of Health
  4. Evaluation of Kininostatin for Treatment of Wet AMD

    Amount: $149,800.00

    DESCRIPTION: Advanced Vision Therapies, Inc. (AVT) is developing novel therapies for ocular disorders that are the major causes of blindness in the developed world. The initial indications are the ne ...

    SBIRPhase I2005Department of Health and Human Services National Institutes of Health
  5. RdCVF as a novel therapeutic for retinitis pigmentosa

    Amount: $311,846.00

    Advanced Vision Therapies, Inc. (AVT) is developing novel therapies for ocular disorders that are the major causes of blindness in the developed world. These diseases include the neovascular ocular di ...

    SBIRPhase I2005Department of Health and Human Services National Institutes of Health
  6. Evaluation of novel BIV-based vectors in primate models

    Amount: $541,836.00

    Advanced Vision Therapies, Inc. (AVT) is developing novel therapies for ocular disorders that are the major causes of blindness in the developed world. These diseases include wet age-related macular d ...

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
  7. Novel Lentiviral Vector with Regulatable Gene Expression

    Amount: $133,891.00

    DESCRIPTION (provided by applicant) Advanced Vision Therapies, Inc. (AV-T) is focused on the treatment of ocular diseases that cause blindness. The primary disease indication is wet age-related macula ...

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
  8. Development of Novel BIV-based Lentiviral Vectors

    Amount: $329,702.00

    DESCRIPTION (provided by applicant): Lentiviral based gene transfer systems represent a promising gene delivery technology due to their ability to efficiently transduce a variety of non-dividing targe ...

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
  9. Novel Therapy for Wet Age-Related Macular Degeneration

    Amount: $223,202.00

    DESCRIPTION (provided by applicant): Wet age-related macular degeneration (AMD) is the leading cause of blindness in the developed world and represents a disease with a great unmet medical need. The b ...

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government